United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

26 May 2017
Change (% chg)

$0.08 (+4.44%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VRML.OQ


Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's... (more)


Beta: 2.36
Market Cap(Mil.): $106.01
Shares Outstanding(Mil.): 56.09
Dividend: --
Yield (%): --


  VRML.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.24 -- --
ROI: -120.73 -8.48 -5.42
ROE: -131.27 -11.31 -4.68

BRIEF-Vermillion Q1 loss per share $0.05

* Q1 revenue $726,000 versus $505,000 Source text for Eikon: Further company coverage:

May 11 2017

BRIEF-Vermillion files for resale of up to 6.6 mln shares of common stock

* Files for resale of up to 6.6 million shares of co's common stock - sec filing Source text - http://bit.ly/2oVnfQO Further company coverage:

Apr 11 2017

BRIEF-Vermillion enters into a contract with TriCare South

* Aspira labs announces tricare south contract Source text for Eikon: Further company coverage:

Mar 30 2017

BRIEF-Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017

* Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017

Mar 13 2017

BRIEF-Vermillion attains out-of-state provider status with Medi-Cal

* Vermillion Inc - attained out-of-state provider status with Medi-Cal, California's medicaid program, for ova1 /multivariate index assay Source text for Eikon: Further company coverage:

Mar 06 2017

BRIEF-Vermillion announces equity financing of $5.6 million

* Vermillion Inc - under terms of private placement,vermillion has agreed to sell 3.7 million shares of its common stock at price of $1.40 per share Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-Vermillion announces reimbursement code updates for Overa and OVA1

* Vermillion Inc - Co and unit Aspira Labs, have received a proprietary laboratory analyses (PLA) code (0003U) for Overa (MIA2G) Source text for Eikon: Further company coverage:

Jan 09 2017

More From Around the Web


  Price Chg
Abbott Laboratories (ABT.N) $44.71 +0.76
Becton Dickinson and Co (BDX.N) $186.48 -0.29
Arrayit Corp (ARYC.PK) $0.01 -0.00

Earnings vs. Estimates